• 16 Nov 20 | CSL | CSL's Sequiris announced it will build a next-generation $800 million influenza vaccine manufacturing facility in Australia. The facility is expected to be operational by mid-2026 and will be the only cell-based influenza vaccine manufacturing fac...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags